Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs
Sponsor: Queen Mary University of London
Summary
We will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by measuring effectiveness of Pakistan-government sponsored current therapies, emergence of viral resistance, consequences of infection (chiefly liver cancer) and through developing models, based on incidence data, determine the proportion of people who need curative treatment to eliminate HCV, and assess whether targeting can optimise this.
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
OBSERVATIONAL
Enrollment
25000
Start Date
2021-11-01
Completion Date
2026-01-30
Last Updated
2025-03-24
Healthy Volunteers
Yes
Conditions
Interventions
HCV RNA (PCR)
We will test HCV positive patients after treatment to observe if they achieve SVR
HCV Antibody test (Point of care)
HCV antibody test used to establish if patients have had or are actively infected with HCV
AST/ALT and platelets measurement
AST/ALT and platelets to determine APRI score
Locations (1)
Aga Khan University
Karachi, Pakistan